Skip to content
value.today

BioCardia, Inc.

BCDA
$16 Mmarket cap on Oct 21, 2026-1.6% since Jan 2024
Compare
World rank
#24,988
Revenue
—
For year ending December-2025
Net income
$-8 M
SEC filing
Employees
—

BioCardia, Inc. in brief

BioCardia, Inc. is a listed company in the Biotechnology industry, based in Sunnyvale, California, USA. Its market value was $16 M on 21 October 2026, which makes it the 24,988th largest listed company in the world and the 4,208th largest in the USA on this site. Peter Altman is its chief executive. Its shares trade under the symbol BCDA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

BioCardia, Inc. timeline

6 events, 1996–2022
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2000
  4. ✎
    Renamed Clicknsettle Com Inc
    Formerly Nam Corp.
  5. 2008
  6. ✎
    Renamed Cardo Medical, Inc.
    Formerly Clicknsettle Com Inc.
  7. 2011
  8. ✎
    Renamed Tiger X Medical, Inc.
    Formerly Cardo Medical, Inc..
  9. 2016
  10. ✎
    Renamed BioCardia, Inc.
    Formerly Tiger X Medical, Inc..
  11. 2022
  12. 💰
    Record revenue of $1 million
    FY2022, the highest of the 6 years on record.

Events of BioCardia, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$14 M$27 M$41 M$54 M2020202120222023202420252026

World rank over time

▼ down 678 places since 2020
2020-01-01: #24327#24,32720202021-01-01: #20660#20,66020212022-01-07: #28843#28,84320222022-12-25: #26839#26,83920222023-07-30: #29335#29,33520232024-01-05: #29661#29,66120242026-03-08: #12535#12,53520262026-08-01: #22367#22,36720262026-10-08: #24861#24,86120262026-10-21: #25005#25,0052026

Rank in USA: #4,413 (Jan 2020) · #4,056 (Jan 2021) · #5,192 (Jan 2022) · #4,992 (Dec 2022) · #5,183 (Jul 2023) · #4,412 (Jan 2024) · #2,354 (Mar 2026) · #3,988 (Aug 2026) · #4,152 (Oct 2026) · #4,210 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
17.5×
Free cash flow yield
-47.3%
Net margin
—
Operating margin
—
Return on equity
-914.4%
Liabilities / assets
73.9%
Revenue growth
-87.5%
R&D / revenue
7316.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-14M$1MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-15M$1MFY19Fiscal year ending Dec 2020: revenue —, net income $-15M—FY20Fiscal year ending Dec 2021: revenue $1M, net income $-13M$1MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-12M$1MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-12M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-8M$0MFY24Fiscal year ending Dec 2025: revenue —, net income $-8M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-8M$-8M—
Dec 2024$0M-87.5%$-8M$-8M-13250.0%
Dec 2023$0M-64.4%$-12M$-12M-2410.4%
Dec 2022$1M+32.4%$-12M$-12M-882.2%
Dec 2021$1M—$-13M$-13M-1237.3%
Dec 2020——$-16M$-15M—
Dec 2019$1M+14.5%$-14M$-15M-2071.8%
Dec 2018$1M—$-14M$-14M-2256.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-7M$0M$-7M——
Dec 2024$-8M$0M$-8M——
Dec 2023$-10M$0M$-10M——
Dec 2022$-11M$0M$-11M——
Dec 2021$-10M$0M$-10M$-0.75—
Dec 2020$-12M$0M$-12M$-1.48—
Dec 2019$-9M$0M$-10M$-2.61—
Dec 2018$-11M$0M$-11M$-3.28—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-2M—Dec ’24Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-1M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-2M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26Three months to Sep 2026: revenue —, net income $-2M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of BioCardia, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-8 M
Net income
$-8 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$3 M
Total liabilities
$3 M
Total equity
$1 M

As of December-2025

Top 21 institutional investors in BioCardia, Inc.#

As of Sep 30, 2026
21 institutions held 1.4 M shares (about 9.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 8.7%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 21 largest institutional investors in BioCardia, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1CM Management, LLC400,000+100,000 (+33.33%)2.64%$0 MNov 12, 2026
2Citigroup Inc275,031-122,563 (-30.83%)1.82%$0 MNov 4, 2026
3Pingora Partners LLC159,582+39,200 (+32.56%)1.05%$0 MNov 13, 2026
4Vanguard Capital Management LLC124,5910 (0.00%)0.82%$0 MNov 13, 2026
5Geode Capital Management, LLC104,713+38,049 (+57.08%)0.69%$0 MNov 6, 2026
6Vanguard Fiduciary Trust Co66,2700 (0.00%)0.44%$0 MNov 13, 2026
7Gsa Capital Partners LLP54,756+41,894 (+325.72%)0.36%$0 MNov 16, 2026
8Brown Advisory Inc48,738+13,200 (+37.14%)0.32%$0 MNov 16, 2026
9HRT Financial LP44,949New0.30%$0 MNov 13, 2026
10Susquehanna International Group, LLP38,817+8 (+0.02%)0.26%$0 MNov 16, 2026
11StoneX Group Inc.33,445+13,425 (+67.06%)0.22%$0 MNov 3, 2026
12Virtu Financial LLC24,142New0.16%$0 MNov 17, 2026
13Wealth Enhancement Advisory Services, LLC18,5000 (0.00%)0.12%$0 MOct 13, 2026
14Citadel Advisors LLC16,691-6,265 (-27.29%)0.11%$0 MNov 16, 2026
15Commonwealth Equity Services, LLC13,383-10,000 (-42.77%)0.09%$0 MNov 2, 2026
16Tower Research Capital LLC (TRC)3,943+756 (+23.72%)0.03%$0 MNov 16, 2026
17Morgan Stanley3,1050 (0.00%)0.02%$0 MNov 13, 2026
18UBS Group AG1,010-76,609 (-98.70%)0.01%$0 MNov 10, 2026
19Global Retirement Partners, LLC4110 (0.00%)0.00%$0 MNov 10, 2026
20SBI Securities Co., Ltd.15+6 (+66.67%)0.00%$0 MOct 22, 2026
21Caitong International Asset Management Co., Ltd8+7 (+700.00%)0.00%$0 MOct 29, 2026

Mutual funds holding BioCardia, Inc.#

7 funds hold shares worth $0 M (about 1.3% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding BioCardia, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.69,023$0 M0.46%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.55,568$0 M0.37%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC59,971$0 M0.40%<0.01%+21%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC10,526$0 M0.07%<0.01%+22%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC3,237$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC964$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC47$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at BioCardia, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$170 K
34 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$170 K
open market only
Insiders on file
27
since
$918 K-$56 K$0Jan 2024: bought $0 (0 trades), sold $56 K (1 trades)Jan 24Feb 2024: bought $50 K (1 trades), sold $0 (0 trades)Mar 2024: bought $195 (1 trades), sold $0 (0 trades)Apr 2024: bought $1 K (1 trades), sold $0 (0 trades)Jun 2024: bought $7 K (4 trades), sold $0 (0 trades)JunJul 2024: bought $915 (1 trades), sold $0 (0 trades)Nov 2024: bought $3 K (1 trades), sold $0 (0 trades)Dec 2024: bought $3 K (2 trades), sold $7 K (1 trades)Jan 2025: bought $2 K (2 trades), sold $0 (0 trades)Jan 25Feb 2025: bought $1 K (1 trades), sold $0 (0 trades)Mar 2025: bought $92 K (4 trades), sold $0 (0 trades)Apr 2025: bought $536 K (14 trades), sold $0 (0 trades)May 2025: bought $6 K (5 trades), sold $0 (0 trades)MayJun 2025: bought $211 K (4 trades), sold $0 (0 trades)Aug 2025: bought $5 K (4 trades), sold $0 (0 trades)Sep 2025: bought $918 K (3 trades), sold $0 (0 trades)Dec 2025: bought $1 K (2 trades), sold $0 (0 trades)DecJan 2026: bought $1 K (2 trades), sold $0 (0 trades)Feb 2026: bought $6 K (1 trades), sold $0 (0 trades)Mar 2026: bought $1 K (2 trades), sold $0 (0 trades)Apr 2026: bought $7 K (3 trades), sold $0 (0 trades)AprMay 2026: bought $12 K (4 trades), sold $0 (0 trades)Jun 2026: bought $110 K (5 trades), sold $0 (0 trades)Jul 2026: bought $20 K (8 trades), sold $0 (0 trades)Aug 2026: bought $7 K (2 trades), sold $0 (0 trades)AugSep 2026: bought $4 K (3 trades), sold $0 (0 trades)Oct 2026: bought $475 (2 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
BioCardia, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Peter AltmanPresident and CEO, DirectorBuy+300$0.950$285385,385Form 4
filed Peter AltmanPresident and CEO, DirectorBuy+200$0.950$190385,085Form 4
filed Peter AltmanPresident and CEO, DirectorBuy+1,000$1.030$1 K384,885Form 4
filed Peter AltmanPresident and CEO, DirectorBuy+1,900$1.050$2 K383,885Form 4
filed Peter AltmanPresident and CEO, DirectorBuy+800$1.090$872381,985Form 4
filed Peter AltmanPresident and CEO, DirectorBuy+5,400$0.930$5 K381,115Form 4
filed Peter AltmanPresident and CEO, DirectorBuy+1,900$0.920$2 K375,785Form 4
filed Peter AltmanPresident and CEO, DirectorBuy+5,000$0.780$4 K373,885Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: BioCardia, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
735,104
6.8% of shares · 6.29 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-04-30 19:58 UTC, code LUDP, resumed 20:00 UTC

Fails to deliver

  • : 4,366 shares at $1.04
  • : 13,609 shares at $1.09
  • : 83,305 shares at $1.05
  • : 96,090 shares at $1.08
  • : 10,178 shares at $1.17

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

BioCardia, Inc. scorecard#

Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 21, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median17.5×Price to book 17.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-47.3%Free cash flow is -47.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$15 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-946.0%-946.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.12 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

BioCardia, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

BioCardia, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue00.10.51.41.00.10.70.60.50.6
Cost of revenue————00.00.40.50.70.7
Research and development5.04.47.78.88.69.88.68.55.83.3
Selling, general and administrative3.33.74.44.45.15.96.05.86.44.1
Total costs and expenses8.38.1121314161515138.2
Operating income−8.3−8.0−12−12−13−16−14−14−12−7.6
Interest and finance income————0.00.0————
Interest expense and finance costs————00.00.1—01.7
Other non-operating income (expense)0.10.10.1−0.00.00.5−0.50.10.1−2.7
Income tax0000000000
Net income attributable to shareholders−8.2−7.9−12−12−13−15−15−14−12−10
Earnings per share, basic-1.23-2.90-8.19r-0.67-0.75-1.48-2.61-3.28r-2.90r-1.23r
Earnings per share, diluted————-0.75-1.48-2.61-3.28r-2.90r-1.23r
Shares, weighted average (basic)6.72.71.4r1817—————
Shares, weighted average (diluted)————17105.64.3r4.2r8.4r
Balance sheet
Cash and cash equivalents2.52.41.1r7.413215.65.41321
Receivables0.000.10.20.10.20.10.30.10.1
Inventory——————0.00.10.20.1
Other current assets0.20.30.30.30.50.4————
Current assets2.72.61.57.913236.46.21322
Property, plant and equipment0.00.00.10.20.20.10.20.10.20.1
Right-of-use (leased) assets0.50.91.31.61.90.61.1———
Total assets3.43.73.09.816237.76.41422
Accounts payable0.60.40.90.70.50.70.90.7r0.90.5
Current liabilities2.42.33.63.63.74.24.02.52.31.4
Lease liabilities (non-current)0.10.61.01.31.600.6———
Total liabilities2.52.94.64.95.34.25.32.62.41.5
Retained earnings−168−160−152r−141−129−116−101−86−72−60
Shareholders' equity0.90.8−1.64.910192.43.81121
Total liabilities and equity3.43.73.09.816237.76.41422
Shares outstanding114.61.6r2017166.84.8r3838r
Cash-flow statement
Depreciation and amortization0.00.10.10.10.10.10.10.10.10.0
Share-based compensation0.40.71.01.21.73.02.72.82.70.9
Cash from operating activities−7.4−7.9r−10.0−11−10−12−9.4−11−8.7−5.5
Capital expenditure−0.0−0.0−0.0−0.1−0.1−0.0−0.1−0.1−0.1—
Cash from investing activities−0.0−0.0−0.0−0.1−0.1−0.0−0.1−0.1−0.119
Shares issued8.7114.45.52.00————
Cash from financing activities7.69.2r3.75.11.9289.83.80.14.4
Change in cash0.11.3−6.3−5.5−8.5160.2———
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at BioCardia, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2024
$493 K
Peter Altman
Other top executives, average
$303 K
the CEO earned 1.6× this
$100 invested is now
$22
BioCardia, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2024Peter Altman$493 K$423 K$303 K$22
2023Peter Altman$863 K$600 K$451 K$32
2022Peter Altman$902 K$907 K$477 K$108

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024

Events at BioCardia, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Directors and officers 1 · Shareholder vote 1 · Results announced 5

BioCardia, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of BioCardia, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2018$4 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Oct 2016$36 MPrivate placement after listing$10 to $50 million192equitySEC
Oct 2009$6 MNo. 2$2 to $10 million74equity, optionsSEC
Jun 2009$3 MNo. 1$2 to $10 million43equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at BioCardia, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2011–2011
Latest
—
2011-01-24
BioCardia, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2011············—
BioCardia, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How BioCardia, Inc. compares in Biotechnology

  • Market cap$16 M · higher than 15% of 726
  • Revenue growth-87.5% · higher than 3% of 438
  • Price / book17.5× · lower than 9% of 534
  • FCF yield-47.3% · higher than 25% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
BioCardia, Inc.🇺🇸$16 M——-87.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 21, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BioCardia, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BioCardia, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BioCardia, Inc.? Suggest a correction